Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
Antoine Dürrbach(Inserm), Josep M. Grinyó(Bellvitge University Hospital), María del Carmen Rial, Flavio Vincenti(University of California, San Francisco), Thomas C. Pearson(Emory Healthcare), Josep M. Campistol(Universitat de Barcelona), Pushkal Garg(Université Paris-Sud), JO Medina Pestana(Hospital do Rim e Hipertensão), J. Xing(Bristol-Myers Squibb (United States)), G. Russo(Bristol-Myers Squibb (United States)), Sander Florman(Mount Sinai Hospital), A. Jay Block(University of Wisconsin–Madison), Valter Duro Garcı́a(Hospital São Vicente)
Cited by 566
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714